Olfactomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Olfactomics is pioneering next-generation volatile organic compound (VOC) analysis by combining its best-in-class differential mobility spectrometry (DMS) hardware with advanced machine learning analytics. The company operates in two primary verticals: industrial applications, such as battery safety and material quality control, and medical diagnostics, with a focus on real-time tissue analysis during cancer surgery. Founded by surgeons and engineers, Olfactomics is translating its platform technology into specific products like IonVision for industrial use and Resect for surgical margin assessment, positioning itself at the intersection of analytical chemistry, AI, and precision medicine.

OncologySurgical Oncology

Technology Platform

Proprietary Differential Mobility Spectrometry (DMS) hardware combined with AI/ML analytics for real-time, high-sensitivity detection and analysis of volatile organic compounds (VOCs) at atmospheric pressure.

Opportunities

The platform's ability to provide real-time, sensitive VOC analysis creates significant opportunities in industrial safety (e.g., battery thermal runaway detection) and quality control, as well as in revolutionizing surgical oncology by providing instant feedback on tissue margins.

The non-invasive nature of VOC analysis also opens vast potential for early disease detection across multiple therapeutic areas.

Risk Factors

Key risks include the high cost and lengthy timeline of clinical validation and regulatory approval for medical devices, competition from established analytical methods, and the challenge of translating a powerful platform into simple, robust, and commercially viable products for diverse markets.

The company's early-stage status also implies dependency on external funding.

Competitive Landscape

Olfactomics competes with established analytical techniques like Gas Chromatography-Mass Spectrometry (GC-MS) and other electronic nose (e-nose) technologies. Its differentiation lies in the combination of DMS's atmospheric pressure operation, millisecond speed, ppb-level sensitivity, and proprietary AI-driven data interpretation. In the medical space, it faces competition from other intraoperative margin assessment tools like frozen section pathology and emerging optical techniques.

More companies in Diagnostics & Precision Medicine →More companies in Finland →